Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - Vaccine, 2021 - Elsevier
Background The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …
被引用次数：9 相关文章

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - 2021 - scholarbank.nus.edu.sg
Background: The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - Vaccine, 2021 - hub.hku.hk
Background: The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - 2021 - cabidigitallibrary.org
Background: The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - Vaccine, 2021 - europepmc.org
Background The nonavalent human papillomavirus (HPV) vaccine has been shown to
extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by …

[引用][C] Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore

LC Phua, HCW Choi, J Wu, M Jit, J Low, K Ng… - 2021